Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma Kyuichi Kadota, MD, PhD, Jun-ichi Nitadori, MD, PhD, Hideki Ujiie, MD, Daniel.

Slides:

Advertisements

Similar presentations

Efficacy and Safety of Pemetrexed Maintenance Therapy versus Best Supportive Care in Patients from East Asia with Advanced, Nonsquamous Non-small Cell.

Advertisements

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

Comprehensive Pathological Analyses in Lung Squamous Cell Carcinoma: Single Cell Invasion, Nuclear Diameter, and Tumor Budding Are Independent Prognostic.

Perioperative versus Preoperative Chemotherapy with Surgery in Patients with Resectable Squamous Cell Carcinoma of Esophagus Yang Zhao, MD, ZhiJun Dai,

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non–Small Cell Lung Cancer: A Randomized, Double-Blind,

A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced.

Spread through Air Spaces (STAS) Is an Independent Predictor of Recurrence and Lung Cancer–Specific Death in Squamous Cell Carcinoma Shaohua Lu, MD,

Usman Ahmad, MD, Haoxian Yang, MD, Camelia Sima, MD, MS, Daniel H

APLCC ORAL ABSTRACT SESSIONS - MONDAY, NOVEMBER 26

Nicolas Girard, MD, Julie Teruya-Feldstein, MD, Eden C

Complement and Correction for Meta-Analysis of Patients with Extensive-Stage Small Cell Lung Cancer Managed with Irinotecan/Cisplatin versus Etoposide/Cisplatin.

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

Gemcitabine and Irinotecan for Patients with Untreated Extensive Stage Small Cell Lung Cancer: SWOG 0119 Wallace Akerley, MD, Jason McCoy, MS, Paul J.

MA12.06 Tumor Spread through Air Spaces (STAS) in Lung Squamous Cell Cancer is an Independent Risk Factor: A Competing Risk Analysis Shaohua Lu, Takashi.

MA12.09 Comparative Histological Subtype Analysis of Lung Adenocarcinoma Tumor and Metastatic Lymph Nodes and the Prognostic Impact Shaohua Lu, Takashi.

Electronic Updates for JTO Readers

Survival after resection of synchronous non–small cell lung cancer

Membrane Carbonic Anhydrase IX Expression and Relapse Risk in Resected Stage I–II Non–Small-Cell Lung Cancer David J. Stewart, MD, Maria I. Nunez, MD,

Pleomorphic Epithelioid Diffuse Malignant Pleural Mesothelioma: A Clinicopathological Review and Conceptual Proposal to Reclassify as Biphasic or Sarcomatoid.

OA20.03 Tumoral IL-7 Receptor is a Potential Target for Lung Adenocarcinoma Immunotherapy Ming-Ching Lee, Takashi Eguchi, Zachary Tano, Kyuichi Kadota,

PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung Cancer Denis Soulières, MD, Fred R.

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for.

Samuel J. Wang, MD, PhD, C David Fuller, MD, Charles R. Thomas, MD

Should Patients with Extrapulmonary Small-Cell Carcinoma Receive Prophylactic Cranial Irradiation? Jarushka Naidoo, MB BcH BAO, MRCPI, Min Yuen Teo,

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

Anya M. Litvak, MD, Paul K. Paik, MD, Kaitlin M. Woo, MS, Camelia S

Distinct Clinical Course of EGFR-Mutant Resected Lung Cancers: Results of Testing of 1118 Surgical Specimens and Effects of Adjuvant Gefitinib and Erlotinib

Liver Metastasis Is Associated with Poor Progression-Free Survival in Patients with Non–Small Cell Lung Cancer Treated with Nivolumab Tomoko Funazo,

A Correlative Biomarker Analysis of the Combination of Bevacizumab and Carboplatin- Based Chemotherapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer:

An Updated Meta-Analysis of Randomized Controlled Trials Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously Untreated.

Second-line or Subsequent Systemic Therapy for Recurrent or Progressive Non-Small Cell Lung Cancer: A Systematic Review and Practice Guideline J Noble,

Clinical Characteristics and Outcomes for Patients With Thymic Carcinoma: Evaluation of Masaoka Staging Anya M. Litvak, MD, Kaitlin Woo, MS, Sara Hayes,

Impact of Positive Nodal Metastases in Patients with Thymic Carcinoma and Thymic Neuroendocrine Tumors Benny Weksler, MD, Anthony Holden, MD, Jennifer.

Effects of Chemotherapy on Survival of Elderly Patients with Small-Cell Lung Cancer: Analysis of the SEER-Medicare Database Laura C. Caprario, MD, MS,

Long-Term Results of a Trial of Concurrent Chemotherapy and Escalating Doses of Radiation for Unresectable Non–Small Cell Lung Cancer: NCCTG N0028 (Alliance)

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

A Prognostic Model to Predict Mortality among Non–Small-Cell Lung Cancer Patients in the U.S. Military Health System Jie Lin, PhD, MPH, Corey A. Carter,

Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non–small cell.

Feiran Lou, MD, MS, Camelia S. Sima, MD, MS, Prasad S

Re-evaluation of the Role of Postoperative Radiotherapy and the Impact of Radiation Dose for Non–Small-Cell Lung Cancer Using the National Cancer Database

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

High SUVmax on FDG-PET Indicates Pleomorphic Subtype in Epithelioid Malignant Pleural Mesothelioma: Supportive Evidence to Reclassify Pleomorphic as Nonepithelioid.

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

PUB016 A Multi-National Cohort Validation of Procedure–Specific Nomograms to Predict Recurrence for Small Lung Adenocarcinomas Sarina Bains, Takashi.

Absence of a Relationship between Tumor 18F-fluorodeoxyglucose Standardized Uptake Value and Survival in Patients Treated with Definitive Radiotherapy.

Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios as Prognostic Factors after Stereotactic Radiation Therapy for Early-Stage Non–Small-Cell Lung Cancer

Prognostic Impact of Node Involvement Pattern in Pulmonary pN1 Squamous Cell Carcinoma Patients Masayuki Nakao, MD, Junji Yoshida, MD, PhD, Genichiro.

Mitotic Inhibitors Journal of Thoracic Oncology

Phase II Study of Bendamustine in Relapsed Chemotherapy Sensitive or Resistant Small-Cell Lung Cancer Philip E. Lammers, MD, Yu Shyr, PhD, Chung-I Li,

Impact of a Multidisciplinary Thoracic Oncology Clinic on the Timeliness of Care Richard F. Riedel, MD, Xiaofei Wang, PhD, Meg McCormack, PA-C, Eric Toloza,

Nabil P. Rizk, MD, Venkatraman E. Seshan, PhD, Manjit S

Gemcitabine in Brief versus Prolonged Low-Dose Infusion, both Combined with Cisplatin, for Advanced Non-small Cell Lung Cancer: A Randomized Phase II.

Comprehensive Pathological Analyses in Lung Squamous Cell Carcinoma: Single Cell Invasion, Nuclear Diameter, and Tumor Budding Are Independent Prognostic.

Immune-Modulating Vaccines in Non-small Cell Lung Cancer

Phase I Study of Lenalidomide in Solid Tumors

Jie Huang, Juan Peng, Linlang Guo, MD, PhD

Should Never-Smokers at Increased Risk for Lung Cancer Be Screened?

Primary Tumor Standardized Uptake Value Measured on F18-Fluorodeoxyglucose Positron Emission Tomography Is of Prediction Value for Survival and Local.

Tivantinib in Combination with Erlotinib versus Erlotinib Alone for EGFR-Mutant NSCLC: An Exploratory Analysis of the Phase 3 MARQUEE Study Giorgio V.

Prognostic Significance of CT-Determined Sarcopenia in Patients with Small-Cell Lung Cancer Eun Young Kim, MD, Young Saing Kim, MD, Inkeun Park, MD,

IASLC 6th Latin American Conference on Lung Cancer

Efficacy and Safety of Cisplatin/Pemetrexed Versus Cisplatin/Gemcitabine as First-Line Treatment in East Asian Patients with Advanced Non-small Cell Lung.

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Concurrent Chemotherapy and Short Course Radiotherapy in Patients with Stage IIIA to IIIB Non-small Cell Lung Cancer Not Eligible for Radical Treatment:

Rogerio C. Lilenbaum, MD, John Cashy, PhD, Thomas A

Effect of Tumor Size on Prognosis in Patients Treated with Radical Radiotherapy or Chemoradiotherapy for Non–Small Cell Lung Cancer: An Analysis of the.

Prognostic Significance of Tumor Size in Patients with Stage III Non–Small-Cell Lung Cancer: A Surveillance, Epidemiology, and End Results (SEER) Survey.

Presentation transcript:

Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma Kyuichi Kadota, MD, PhD, Jun-ichi Nitadori, MD, PhD, Hideki Ujiie, MD, Daniel H. Buitrago, MD, Kaitlin M. Woo, MS, Camelia S. Sima, MD, MS, William D. Travis, MD, David R. Jones, MD, FACS, Prasad S. Adusumilli, MD, FACS, FCCP Journal of Thoracic Oncology Volume 10, Issue 9, Pages 1301-1310 (September 2015) DOI: 10.1097/JTO.0000000000000617 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 CD10+ neutrophil and CD20+ lymphocyte infiltration in tumors. A, Tumor with high CD10+ neutrophil infiltration and low CD20+ lymphocyte infiltration. B, Tumor with low CD10+ neutrophil infiltration and high CD20+ lymphocyte infiltration. Journal of Thoracic Oncology 2015 10, 1301-1310DOI: (10.1097/JTO.0000000000000617) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Overall survival (OS) of combination of CD10+ neutrophil and CD20+ lymphocyte infiltration in the training cohort. A, OS of patients with high CD10+ neutrophil and low CD20+ lymphocyte infiltration (5-year OS, 42%) was significantly worse compared with those with low CD10/low CD20 (5-year OS, 62%; p = 0.001; hazard ratio [HR] = 0.55; 95% confidence interval [CI] = 0.38–0.79), low CD10/high CD20 (5-year OS, 55%; p = 0.026; HR = 0.58; 95% CI = 0.36–0.94), and high CD10/high CD20 (5-year OS, 70%; p = 0.043; HR = 0.60; 95% Cl = 0.36–0.98). B, OS of patients with high CD10/CD20 risk index was significantly worse (n = 72; 5-year OS, 42%) than those with low-risk index (n = 228; 5-year OS, 62%; P < 0.001; HR = 0.56; 95% CI = 0.4–0.78). Journal of Thoracic Oncology 2015 10, 1301-1310DOI: (10.1097/JTO.0000000000000617) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Overall survival (OS) of combination of CD10+ neutrophil and CD20+ lymphocyte infiltration in the validation cohort. A, OS of patients with high CD10+ neutrophil and low CD20+ lymphocyte infiltration (5-year OS, 46%) was relatively worse compared with those with low CD10/low CD20 (5-year OS, 58%; p = 0.069; hazard ratio [HR] = 0.61; 95% confidence interval [CI] = 0.36–1.04), low CD10/high CD20 (5-year OS, 84%; p = 0.10; HR = 0.55; 95% CI = 0.27–1.13), and high CD10/high CD20 (5-year OS, 71%; p = 0.092; HR = 0.52; 95% Cl = 0.24–1.11). B, OS of patients with high CD10/CD20 risk index was significantly worse (n = 30; 5-year OS, 46%) than those with low-risk index (n = 112; 5-year OS, 66%; p = 0.032; HR = 0.58; 95% Cl = 0.3––0.96). Journal of Thoracic Oncology 2015 10, 1301-1310DOI: (10.1097/JTO.0000000000000617) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions